

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. to 3. **(canceled)**

4. **(withdrawn)** An axon growth stimulation kit as defined in claim 1 wherein said therapeutically acceptable matrix is a fibrin matrix.

5. to 6. **(canceled)**

7. **(withdrawn)** A biocompatible composition as defined in claim 5 wherein said therapeutically acceptable matrix is a fibrin matrix.

8. **(withdrawn)** A method for the preparation of a flowable biocompatible composition comprising admixing (i) at least one supplement selected from the group consisting of therapeutically active agents for facilitating axon growth and (ii) a flowable carrier component capable of forming a therapeutically acceptable matrix in vivo at a nerve lesion site; wherein said supplement is releasable from said matrix into the adjacent external environment.

9. **(withdrawn)** A method as defined in claim 8 wherein said therapeutically acceptable matrix is a collagen matrix.

10. **(withdrawn)** A method as defined in claim 8 wherein said therapeutically acceptable matrix is a fibrin matrix.

11. **(new)** An axon sprouting stimulation kit comprising

- a first container comprising a flowable collagen matrix,
- a second container comprising a matrix-releasable therapeutically active agent,
- a mixing means for intermingling the flowable collagen matrix and the matrix-releasable therapeutically active agent into a therapeutically acceptable matrix,

and;

- a delivery means,

wherein the matrix-releasable therapeutically active agent is selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at a nerve lesion

site.

12. **(new)** The axon sprouting stimulation kit of claim 11, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum and a recombinant C3 retaining ADP-ribosylation activity.

13. **(new)** The axon sprouting stimulation kit of claim 11, further comprising a protease inhibitor.

14. **(new)** The axon sprouting stimulation kit of claim 13, wherein said protease inhibitor is aprotinin.

15. **(new)** The axon sprouting stimulation kit of claim 13, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum and a recombinant C3 retaining ADP-ribosylation activity.

16. **(new)** An axon sprouting stimulation kit comprising

- a container comprising a flowable collagen matrix and a matrix-releasable therapeutically active agent, and;
- a delivery means,

wherein the matrix-releasable therapeutically active agent is selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting at a nerve lesion site.

17. **(new)** The axon sprouting stimulation kit of claim 16, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium botulinum and a recombinant C3 retaining ADP-ribosylation activity.

18. **(new)** The axon sprouting stimulation kit of claim 16, further comprising a protease inhibitor.

19. **(new)** The axon sprouting stimulation kit of claim 18, wherein said protease inhibitor is aprotinin.

20. **(new)** The axon sprouting stimulation kit of claim 18, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from Clostridium

botulinum and a recombinant C3 retaining ADP-ribosylation activity.

21. **(new)** A biocompatible composition for facilitating axon sprouting, said composition comprising: (i) a therapeutically active agent selected from the group consisting of C3 and Y-27632 for facilitating axon sprouting, and (ii) a flowable collagen matrix.

22. **(new)** The biocompatible composition of claim 21, wherein C3 is selected from the group consisting of ADP-ribosyl transferase C3 derived from *Clostridium botulinum*, and a recombinant C3 retaining ADP-ribosylation activity.